Hepatitis B Virus Vaccine – Epidemiology – Europe
Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in Europe (Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Netherlands, Norway, Poland, Portugal, Sweden, Switzerland). We report the population recommended to receive the HBV vaccine for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 20 years for the pharmaceutical markets in Europe.
Clarivate Epidemiology’s HBV vaccine forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the HBV vaccine-eligible population over the forecast period?
All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts two HBV vaccine patient populations, as follows:
- Vaccine-eligible population.
- Population newly eligible for the vaccine.
Note: Coverage may vary by country and region.
